Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164616 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6277 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1271236 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27882748 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8108955 | 1.00 | LMNA (0.67) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| Water SCHEMBL8429009 | 0.98 | LMNA (0.65) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28442347 | 0.98 | LMNA (0.65) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28736318 | 0.89 | LMNA (0.61) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28736239 | 0.89 | SMN1; SMN2 (0.61) | LMNAHPGDHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28736268 | 0.89 | NPC1 (0.61) | LMNAHPGDHDAC1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694660-B1 | PROCESS FOR THE PREPARATION OF ANHYDROUS AND HYDRATED ACTIVE PHARMACEUTICAL INGREDIENTS (APIS); STABLE PHARMACEUTICAL COMPOSITIONS PREPARED FROM THE SAME AND USES OF SAID COMPOSITIONS | QUIRAL QUIMICA DO BRASIL (BR) | 2009-04-08 | — | — | EP | claimed |
| CN-101365440-A | Methods of treating cancer with SAHA, carboplatin, and paclitaxel, and other combination therapies | MERCK & CO INC (US) | 2009-02-11 | — | — | CN | claimed |
| EP-1942884-A2 | METHODS OF TREATING CANCERS WITH SAHA, CARBOPLATIN, AND PACLITAXEL AND OTHER COMBINATION THERAPIES | Merck and Co., Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| WO-2007056162-A2 | METHODS OF TREATING CANCERS WITH SAHA, CARBOPLATIN, AND PACLITAXEL AND OTHER COMBINATION THERAPIES | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | claimed |
| EP-1492523-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-05 | — | — | EP | claimed |
| EP-1483401-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-08 | — | — | EP | claimed |
| EP-1368328-A1 | METHODS FOR PREPARING NEW TAXOIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2003-12-10 | — | — | EP | claimed |
| WO-2003076660-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | WO | claimed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | claimed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | claimed |
| WO-2002070498-A1 | METHODS FOR PREPARING NEW TAXOIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA, S.A. (FR) | 2002-09-12 | — | — | WO | claimed |
| US-5663393-A | CYCLIZATION; DECYCLIZATION; HYDROLYSIS; HYDROGENATION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-09-02 | — | — | US | claimed |
| US-5602272-A | Reduction and resolution methods for the preparation of compounds useful as intemediates for preparing taxanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996022984-A9 | METHOD FOR PREPARING 4,10-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β-DIHYDROXY-9-OXO-TAX-11-EN-13α-YL (2R,3S)-3-BENZOYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | — | 1996-10-31 | — | — | WO | claimed |
| CN-1123030-A | Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextrins, its preparation and use | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1996-05-22 | — | — | CN | claimed |
| EP-0643626-A4 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL. | RES CORP TECHNOLOGIES INC (US) | 1995-12-06 | — | — | EP | claimed |
| WO-1995008994-A1 | ANTINEOPLASTIC COMBINATION OF TAXOL AND TIAZOFURIN | INDIANA UNIVERSITY FOUNDATION (US) | 1995-04-06 | — | — | WO | claimed |
| EP-0643626-A1 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-03-22 | — | — | EP | claimed |
| WO-1993010076-A1 | SYNTHESIS AND OPTICAL RESOLUTION OF THE TAXOL SIDE CHAIN AND RELATED COMPOUNDS | THE UNIVERSITY OF MISSISSIPPI (US) | 1993-05-27 | — | — | WO | claimed |
| WO-1993003838-A1 | CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | LMNA 4056/4885HPGD 257/4885HDAC1 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.